Plain-English translation of NCT06682962 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a device called the OkuStim System, which uses gentle electrical stimulation applied to the eye once a week. The therapy has already shown promise in slowing vision loss for people with other retinal diseases, and researchers now want to see if it can help people with glaucoma preserve their sight longer. Half of the participants will receive real electrical stimulation, and half will receive a sham (fake) treatment, so researchers can fairly measure whether the therapy actually works.
Glaucoma causes progressive vision loss that can't currently be fully stopped, even with eye drops and other standard treatments. This trial exists to explore whether this treatment might offer an additional way to slow vision decline and help people keep their useful vision for longer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll visit the study center once a week for 18 months to receive a 30-minute electrical stimulation treatment to one eye. You'll also continue taking your regular glaucoma eye drops at home as you normally would. Half of participants will receive the real electrical stimulation therapy, and half will receive a sham treatment — neither you nor your doctor will know which group you're in. Throughout the study, your vision and visual field will be tested periodically to see whether the treatment is helping slow your vision loss.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Germany